Literature DB >> 34478035

Moderate Prognostic Value of lncRNA FOXD2-AS1 in Gastric Cancer with Helicobacter pylori Infection.

Ali Rajabi1, Sepideh Bastani2, Melika Maydanchi3, Samaneh Tayefeh-Gholami1, Sepehr Abdolahi4, Ali Saber3, Reza Safaralizadeh5.   

Abstract

PURPOSE: Gastric cancer (GC) is one of the most frequent tumors worldwide and identification of a sensitive and specific prognostic biomarker is of great importance. Long non-coding RNAs (lncRNAs) play crucial roles in tumorigenesis of various malignancies. In the present study, we investigated lncRNA FOXD2-AS1 expression in gastric tumors and assessed its potential as a prognostic biomarker.
METHODS: A total of 95 tumor and corresponding adjacent non-tumor tissue specimens were collected from patients with GC from Imam Reza hospital, Tabriz, Iran. Total RNA was isolated and FOXD2-AS1 expression was measured using quantitative reverse transcriptase (qRT)-PCR.
RESULTS: FOXD2-AS1 was significantly upregulated in tumor samples as compared to non-tumor tissues (P < 0.0001). In addition, higher expression of FOXD2-AS1 was significantly associated with lymph node metastasis and Helicobacter pylori infection. The receiver operating characteristic (ROC) curve analysis revealed that FOXD2-AS1 might be served as a potential prognostic biomarker for GC.
CONCLUSION: FOXD2-AS1 is upregulated in gastric tumors and can be used as a valuable biomarker in the prognosis of patients with GC.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; FOXD2-AS1; Gastric cancer; H. pylori; LncRNA; Non-coding RNA

Mesh:

Substances:

Year:  2021        PMID: 34478035     DOI: 10.1007/s12029-021-00686-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  6 in total

1.  Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis.

Authors:  Alfred S L Cheng; May S Li; Wei Kang; Victoria Y Cheng; Jian-Liang Chou; Suki S Lau; Minnie Y Go; Ching C Lee; Thomas K Ling; Enders K Ng; Jun Yu; Tim H Huang; Ka F To; Michael W Chan; Joseph J Y Sung; Francis K L Chan
Journal:  Gastroenterology       Date:  2012-10-08       Impact factor: 22.682

2.  Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway.

Authors:  X Yang; B Duan; X Zhou
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-08       Impact factor: 3.507

Review 3.  Emerging roles of lncRNA in cancer and therapeutic opportunities.

Authors:  Ming-Chun Jiang; Jiao-Jiao Ni; Wen-Yu Cui; Bo-Ya Wang; Wei Zhuo
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

4.  Upregulation of the long non-coding RNA FOXD2-AS1 is correlated with tumor progression and metastasis in papillary thyroid cancer.

Authors:  Hongqiang Li; Qicai Han; Yali Chen; Xiaolong Chen; Runsheng Ma; Qungang Chang; Detao Yin
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 5.  Burden of Gastric Cancer.

Authors:  Aaron P Thrift; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-27       Impact factor: 11.382

6.  Microarray analysis of Long non-coding RNA expression profiles in human gastric cells and tissues with Helicobacter pylori Infection.

Authors:  Hong Zhu; Qiang Wang; Yizheng Yao; Jian Fang; Fengying Sun; Ying Ni; Yixin Shen; Hua Wang; Shihe Shao
Journal:  BMC Med Genomics       Date:  2015-12-21       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.